Roche Holding AG on Tuesday said it would pay $2.4 billion to buy the shares it doesn’t already own in Foundation Medicine Inc., furthering its bet on personalized cancer care.
The Swiss drug giant, which already owns roughly 57% of Foundation, will pay $137 a share for the U.S.-based company, valuing it at $5.3 billion.
Cambridge, Mass.-based...